<DOC>
	<DOCNO>NCT00626769</DOCNO>
	<brief_summary>BACKGROUND : Recent evidence show phytoestrogen genistein positively affect bone metabolism clinically significant adverse effect cohort osteopenic , postmenopausal woman . However , still knowledge gap regard long-term safety genistein breast , uterus , thyroid gland efficacy postmenopausal woman . OBJECTIVE : To assess safety profile genistein mammary thyroid gland endometrium cardiovascular apparatus effect bone metabolism 3-year therapy pure , standardize genistein ( 54 mg/day ) .</brief_summary>
	<brief_title>Third Year Evaluation Genistein Efficacy Safety</brief_title>
	<detailed_description>DESIGN : The parent study randomize , double-blind , placebo-controlled trial involve 389 osteopenic , postmenopausal woman 24 month . After 24-month visit , sub-population ( 138 patient ) accept continue intervention 36 month , thus generate follow-up study . SETTING : 3 Italian university medical center . INTERVENTIONS : Participants receive 54 mg genistein , daily , ( n=71 ) placebo ( n=67 ) . Both intervention placebo contain calcium vitamin D3 . All patient also receive dietary instruction isocaloric fat-reduced diet . MEASUREMENTS : Mammographic breast density baseline 24 36 month assess visual classification scale digitize quantification . BRCA1 BRCA2 molecular message , sister chromatid exchange endometrial thickness also evaluate time point . Measurements lumbar spine femoral neck BMD QUS t-score assayed patient . Secondary outcome serum level B-ALP , IGF-I , sRANKL , osteoprotegerin urinary excretion CTX , pyridinoline deoxypyridinoline . Furthermore insulin resistance ( HOMA-IR ) , glucose level , homocysteine hot flush also evaluate . In addition thyroid safety TSH , fT3 , fT4 , thyroid autoantibody , mRNA thyroid retinoid receptor evaluate .</detailed_description>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Good general health Have menstrual period precede year Had undergone surgically induce menopause Had folliclestimulating hormone level &gt; 50 IU/liter serum 17 betaestradiol level â‰¤ 100 pmol/liter Established osteopenia ( 1 &lt; Tscore &lt; 2.5 SD ) Clinical laboratory evidence confound systemic disease , cardiovascular , hepatic , renal disorder Coagulopathy , use oral transdermal estrogen , progestin , androgen steroid Biphosphonates , cholesterollowering therapy cardiovascular medication precede six month Smoking habit two cigarette per day Previous treatment drug could affect skeleton precede year A family history estrogendependent cancer BMD femoral neck &gt; 0.795 g/cm2 ; BMD value correspond T score 1 standard deviation</criteria>
	<gender>Female</gender>
	<minimum_age>49 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Genistein</keyword>
	<keyword>Bone mineral density</keyword>
	<keyword>digital mammography</keyword>
	<keyword>safety</keyword>
</DOC>